Mizuho initiated coverage on Syndax Pharmaceuticals with a new price target
$SNDX
Biotechnology: Pharmaceutical Preparations
Health Care
Mizuho initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $45.00
Get the next $SNDX alert in real time by email
Get the next $SNDX alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $SNDX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $37.00 | Buy | UBS |
| 6/28/2024 | $37.00 | Buy | Jefferies |
| 1/31/2024 | $36.00 → $23.00 | Sector Outperform → Sector Perform | Scotiabank |
| 12/22/2023 | $45.00 | Buy | Mizuho |
| 10/25/2023 | $29.00 | Buy | BofA Securities |
| 10/11/2023 | $30.00 | Buy | Goldman |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 7/11/2023 | $40.00 | Buy | Guggenheim |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan
Syndax Announces Participation in March Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ETBarclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET A live webcast of the fireside chats will be available
UBS initiated coverage on Syndax Pharmaceuticals with a new price target
UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Jefferies initiated coverage on Syndax Pharmaceuticals with a new price target
Jefferies initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Syndax Pharmaceuticals downgraded by Scotiabank with a new price target
Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and set a new price target of $23.00 from $36.00 previously
Chief Financial Officer Goldan Keith A. bought $25,037 worth of shares (1,250 units at $20.03), increasing direct ownership by 2% to 52,623 units (SEC Form 4)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Chief Executive Officer Metzger Michael A exercised 6,074 shares at a strike of $7.20, increasing direct ownership by 2% to 306,195 units (SEC Form 4)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Chief Executive Officer Metzger Michael A exercised 7,814 shares at a strike of $7.20 and sold $117,564 worth of shares (7,814 units at $15.05) (SEC Form 4)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Chief Financial Officer Goldan Keith A. sold $58,559 worth of shares (3,777 units at $15.50), decreasing direct ownership by 4% to 90,746 units (SEC Form 4)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.
SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SEC Form 144 filed by Syndax Pharmaceuticals Inc.
144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SEC Form S-8 filed by Syndax Pharmaceuticals Inc.
S-8 - Syndax Pharmaceuticals Inc (0001395937) (Filer)
FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC
Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section o
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass., Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company develop
Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)